ERBB2 and breast cancer: Anti-HER2 therapy lapatinib was associated with longer times between CNS metastasis and BC-LMD (Additional file 2: Fig. S2, p = 0.026) for HER2 + BC-LMD patients (n = 10) when compared to patients of any subtype who did not receive this treatment.